CN113905733A - 用于消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂 - Google Patents

用于消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂 Download PDF

Info

Publication number
CN113905733A
CN113905733A CN202080041224.0A CN202080041224A CN113905733A CN 113905733 A CN113905733 A CN 113905733A CN 202080041224 A CN202080041224 A CN 202080041224A CN 113905733 A CN113905733 A CN 113905733A
Authority
CN
China
Prior art keywords
candida
compound
colonization
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080041224.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·安古洛·冈萨雷斯
S·A·巴拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of CN113905733A publication Critical patent/CN113905733A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN202080041224.0A 2019-05-16 2020-05-12 用于消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂 Pending CN113905733A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849019P 2019-05-16 2019-05-16
US62/849,019 2019-05-16
PCT/US2020/032547 WO2020232037A1 (en) 2019-05-16 2020-05-12 Antifungal agents, like ibrexafungerp for candida auris decolonization

Publications (1)

Publication Number Publication Date
CN113905733A true CN113905733A (zh) 2022-01-07

Family

ID=70861571

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080041224.0A Pending CN113905733A (zh) 2019-05-16 2020-05-12 用于消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂

Country Status (14)

Country Link
US (1) US20220211684A1 (https=)
EP (1) EP3968986A1 (https=)
JP (2) JP7770191B2 (https=)
KR (1) KR20220009416A (https=)
CN (1) CN113905733A (https=)
AU (1) AU2020276595B2 (https=)
BR (1) BR112021022876A2 (https=)
CA (1) CA3140637A1 (https=)
EA (1) EA202193146A1 (https=)
IL (1) IL288165B1 (https=)
MA (1) MA55958A (https=)
MX (1) MX2021013899A (https=)
TW (2) TWI881977B (https=)
WO (1) WO2020232037A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006380A (ko) 2023-07-03 2025-01-13 연세대학교 산학협력단 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019203A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
US20180325919A1 (en) * 2017-04-10 2018-11-15 Scynexis, Inc. Antifungal agents used in combination
WO2018213641A1 (en) * 2017-05-17 2018-11-22 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of candida species
WO2019028034A1 (en) * 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
MA43825A (fr) * 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
US20220117948A1 (en) * 2019-01-30 2022-04-21 Scynexis, Inc. Triterpenoid antifungals for the treatment of fungal osteo-articular infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019203A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
US20180325919A1 (en) * 2017-04-10 2018-11-15 Scynexis, Inc. Antifungal agents used in combination
WO2018213641A1 (en) * 2017-05-17 2018-11-22 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of candida species
WO2019028034A1 (en) * 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ELIZABETH L. BERKOW: "In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 61, no. 7, pages 1 - 2 *
EMILY LARKIN, BA ET AL: "The Emerging Candida auris: Characterization of Growth 1 Phenotype, Virulence Factors, Antifungal Activity, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation", ANTIMICROB. AGENTS CHEMOTHER., pages 56 - 58 *
MATTHEW WILLIAM MCCARTHY ET AL: "Containment strategies to address the expanding threat of multidrug-resistant Candida auris", EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, vol. 15, no. 12, pages 1097 *
刘昱: "新型抗真菌药物研究进展", 中国真菌学杂志, vol. 13, no. 2 *

Also Published As

Publication number Publication date
TW202110441A (zh) 2021-03-16
EA202193146A1 (ru) 2022-02-11
US20220211684A1 (en) 2022-07-07
CA3140637A1 (en) 2020-11-19
MX2021013899A (es) 2022-02-10
IL288165B1 (en) 2026-01-01
KR20220009416A (ko) 2022-01-24
EP3968986A1 (en) 2022-03-23
AU2020276595A1 (en) 2021-12-09
AU2020276595B2 (en) 2025-12-04
TWI881977B (zh) 2025-05-01
WO2020232037A1 (en) 2020-11-19
JP2025118765A (ja) 2025-08-13
BR112021022876A2 (pt) 2022-04-12
JP2022532734A (ja) 2022-07-19
TW202602460A (zh) 2026-01-16
JP7770191B2 (ja) 2025-11-14
MA55958A (fr) 2022-03-23
IL288165A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
JP2893035B2 (ja) 増強された抗菌剤組成物
WO2018102407A1 (en) Methods for preventing fungal infections
US9839634B2 (en) Antibacterial agents: combination of a rifamycin and a switch region inhibitor
CN106620649A (zh) 使用单剂量奥利万星的治疗方法
JP2025118765A (ja) カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤
CN107073124B (zh) 增效的抗微生物剂
BR112020002290A2 (pt) métodos de tratamento de uma infecção fúngica em um indivíduo em necessidade do mesmo, de prevenção de uma infecção fúngica em um indivíduo, e de tratamento de infecção por candidíase vulvovaginal (vvc) em um indivíduo em necessidade do mesmo
JP6842088B2 (ja) 抗真菌活性を有する組成物
CN113332277B (zh) 一种吡咯二酮化合物在制备抗真菌药物中的应用
CN107236022B (zh) 细胞穿透肽的亲脂性化合物偶联物及其在抗菌中的应用
HK40067174A (zh) 用於消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂
WO2016000504A1 (zh) 磷酸萘酚喹在制备抗菌药物中的用途
CN113498343A (zh) 用于治疗真菌性骨关节感染的三萜抗真菌剂
EA048874B1 (ru) Противогрибковые агенты для деколонизации candida auris
CN113456641B (zh) 一种化合物在制备抗真菌药物中的应用
WO2007092590A2 (en) Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa)
Attas Development of New Strategy to Combat New Fungal Strain” Candida Auris
JP2022523212A (ja) ニューモシスチス属種（Ｐｎｅｕｍｏｃｙｓｔｉｓ ｓｐｐ．）肺炎を治療又は予防するためのトリテルペノイド系抗真菌薬
HK40062347A (en) Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia
CN113710248A (zh) 抗真菌剂
EA051506B1 (ru) Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций
Brown et al. O142 Once daily, levofloxacin 750 mg for 5 days in the treatment of acute pyelonephritis and associated bacteraemia
US20030181425A1 (en) Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment
JP2003137791A (ja) マクロライド化合物による腎炎治療剤。
CN109310735A (zh) 新阳离子肽spr741对抗生素活性的增效作用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40067174

Country of ref document: HK